Genprex (NASDAQ:GNPX) Issues Earnings Results

Genprex (NASDAQ:GNPX) announced its quarterly earnings results on Friday. The company reported ($5.30) earnings per share (EPS) for the quarter, FiscalAI reports.

Genprex Price Performance

Shares of Genprex stock traded down $0.13 on Friday, hitting $2.08. The company had a trading volume of 11,447 shares, compared to its average volume of 165,495. The business has a 50-day simple moving average of $2.65 and a 200-day simple moving average of $17.86. The company has a market cap of $1.71 million, a PE ratio of -0.02 and a beta of -0.95. Genprex has a 52 week low of $1.71 and a 52 week high of $98.78.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

About Genprex

Genprex, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s approach is based on delivering therapeutic genes to diseased cells using non-viral delivery systems, including lipid nanoparticles. Genprex’s lead program, REQORSA Immunogene Therapy, is designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. The company has been evaluating REQORSA in combination with established treatments for non-small cell lung cancer, including targeted and immune-based therapies.